← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA4028.9x13.2x19.5x
EV / LTM revenue5890.9x1.9x3.7x
Premium to unaffected price51221%33%51%
Premium to 30-day VWAP8915%36%48%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
033652009: 4 deals, 1 clean on every measure200942010: 52 deals, 15 clean on every measure2010522011: 56 deals, 39 clean on every measure2011562012: 62 deals, 57 clean on every measure2012622013: 65 deals, 57 clean on every measure2013652014: 50 deals, 46 clean on every measure2014502015: 53 deals, 51 clean on every measure2015532016: 57 deals, 54 clean on every measure2016572017: 57 deals, 49 clean on every measure2017572018: 59 deals, 56 clean on every measure2018592019: 54 deals, 52 clean on every measure2019542020: 25 deals, 24 clean on every measure2020252021: 63 deals, 56 clean on every measure2021632022: 45 deals, 44 clean on every measure2022452023: 42 deals, 32 clean on every measure2023422024: 52 deals, 48 clean on every measure2024522025: 49 deals, 43 clean on every measure2025492026: 26 deals, 19 clean on every measure202626
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Financials: 21.0x median across 8 dealsFinancials21.0xn=8Technology: 19.0x median across 82 dealsTechnology19.0xn=82Healthcare: 18.4x median across 43 dealsHealthcare18.4xn=43Real Estate: 17.2x median across 19 dealsReal Estate17.2xn=19Industrials: 13.8x median across 66 dealsIndustrials13.8xn=66Business Services: 13.2x median across 23 dealsBusiness Services13.2xn=23Utilities: 11.2x median across 30 dealsUtilities11.2xn=30Other: 10.9x median across 17 dealsOther10.9xn=17Materials: 10.2x median across 17 dealsMaterials10.2xn=17Energy: 9.8x median across 15 dealsEnergy9.8xn=15Consumer & Retail: 9.6x median across 65 dealsConsumer & Retail9.6xn=65Media & Telecom: 9.3x median across 17 dealsMedia & Telecom9.3xn=17
Deals by sector
Technology: 189 dealsTechnology189Healthcare: 149 dealsHealthcare149Industrials: 112 dealsIndustrials112Consumer & Retail: 89 dealsConsumer & Retail89Financials: 89 dealsFinancials89Business Services: 51 dealsBusiness Services51Real Estate: 39 dealsReal Estate39Utilities: 35 dealsUtilities35Energy: 31 dealsEnergy31Materials: 31 dealsMaterials31Media & Telecom: 31 dealsMedia & Telecom31Other: 25 dealsOther25
Deals by buyer type
Financial sponsor: 43 dealsFinancial sponsor43Strategic: 871 dealsStrategic871Management / founder: 0 dealsManagement / founder0Controlling holder: 0 dealsControlling holder0Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 626 dealsUnclassified626
Deals by enterprise value
Under $250m: 265 dealsUnder $250m265$250m to $1bn: 214 deals$250m to $1bn214$1bn to $5bn: 264 deals$1bn to $5bn264$5bn to $20bn: 105 deals$5bn to $20bn105Over $20bn: 18 dealsOver $20bn18Not computed: 5 dealsNot computed5
Deals by industry code
Business Services & Software: 140 dealsBusiness Services & Sof…140Chemicals, Pharmaceuticals & Allied Products: 93 dealsChemicals, Pharmaceutic…93Electronics & Electrical Equipment: 88 dealsElectronics & Electrica…88Instruments, Medical Devices & Optical Goods: 64 dealsInstruments, Medical De…64Industrial Machinery & Computers: 39 dealsIndustrial Machinery & …39Electric, Gas & Sanitary Services: 35 dealsElectric, Gas & Sanitar…35Depository Institutions: 35 dealsDepository Institutions35Holding & Other Investment Offices: 32 dealsHolding & Other Investm…32Insurance Carriers: 29 dealsInsurance Carriers29Health Services: 25 dealsHealth Services25
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
AtaiBeckley Inc.
2026-07-15 · Public merger · $6.75 a share
Held out of the multiples: EV / LTM revenue 519.8x above 60x
Eli Lilly
Strategic
Healthcare$2.3bnn.a.519.8x
n.a.
40% to VWAP
DEFM14A
All cash
Crinetics Pharmaceuticals, Inc.
2026-07-06 · Public merger · $85.00 a share
Held out of the multiples: EV / LTM revenue 183.8x above 60x
Vertex Pharmaceuticals Incorporated
Strategic
Healthcare$7.8bnn.a.183.8x
101%
DEFM14A
All cash
Theravance Biopharma, Inc.
2026-06-28 · Public merger · $17.00 a share
Held out of the multiples: EV / LTM EBITDA 172.0x outside 1x to 75x
Zymeworks Inc.
Strategic
Healthcare$482m172.0x4.4x
n.a.
DEFM14A
All cash
Arcosa, Inc.
2026-06-21 · Public merger · $150.00 a share
CRH Americas, Inc.
Strategic
Industrials$8.7bn15.7x3.1x
10%
DEFM14A
All cash
Apogee Therapeutics, Inc.
2026-06-18 · Public merger · $135.11 a share
Andor LLC, Inc.
Strategic
Healthcare$9.1bnn.a.n.a.
53%
DEFM14A
All cash
Taylor Morrison Home Corp
2026-05-31 · Public merger · $72.50 a share
Berkshire Hathaway Inc.
Strategic
Other$8.5bnn.a.1.1x
24%
DEFM14A
All cash
LiveRamp Holdings, Inc.
2026-05-16 · Public merger · $38.50 a share
MMS USA Holdings, Inc.
Strategic
Technology$1.9bn19.9x2.4x
30%
DEFM14A
All cash
NSTS Bancorp, Inc.
2026-05-12 · Public merger · $14.28 a share
Held out of the multiples: EV / LTM revenue 105.7x above 60x
Brookfield Bancshares, Inc.
Strategic
Financials$32mn.a.105.7x
n.a.
DEFM14A
All cash
Catalyst Pharmaceuticals, Inc.
2026-05-06 · Public merger · $31.50 a share
Angelini Pharma S.p.A.
Strategic
Healthcare$3.1bn11.6x5.2x
21%
DEFM14A
All cash
First Seacoast Bancorp, Inc.
2026-05-04 · Public merger · $17.25 a share
Held out of the multiples: no balance sheet at announcement: EV = equity value
Cambridge Savings Bank
Strategic
Financials$81mn.a.n.a.
n.a.
DEFM14A
All cash
Organon & Co.
2026-04-26 · Public merger · $14.00 a share
Sun Pharmaceutical Holdings USA, Inc.
Strategic
Healthcare$11bnn.a.1.8x
103%
120% to VWAP
DEFM14A
All cash
TruBridge, Inc.
2026-04-23 · Public merger · $26.25 a share
Inventurus Knowledge Solutions, Inc.
Strategic
Technology$520m30.9x1.5x
88%
DEFM14A
All cash
Electro Sensors Inc
2026-04-20 · Public merger · $7.75 a share
Inc.
Strategic
Industrials$17mn.a.1.6x
75%
DEFM14A
All cash
Affinity Bancshares, Inc.
2026-03-30 · Public merger · $23.00 a share
Affinity Bank
Strategic
Financials$86mn.a.n.a.
n.a.
DEFM14A
All cash
Olaplex Holdings, Inc.
2026-03-26 · Public merger · $2.06 a share
Held out of the multiples: EV / LTM EBITDA 193.5x outside 1x to 75x
Henkel US Operations Corporation
Strategic
Materials$1.4bn193.5x3.3x
57%
44% to VWAP
DEFM14C
All cash
Talkspace, Inc.
2026-03-09 · Public merger · $5.25 a share
Held out of the multiples: EV / LTM EBITDA 138.7x outside 1x to 75x
Universal Health Services, Inc.
Strategic
Healthcare$832m138.7x3.6x
10%
DEFM14A
All cash
DyTb, LLC
2026-03-04 · Public merger · $0.30 a share
USA Rare Earth, Inc.
Strategic
Materials$21mn.a.n.a.
n.a.
DEFM14A
All cash
Farmer Brothers Co
2026-03-03 · Public merger · $1.29 a share
Farmer Bros. Co.
Strategic
Consumer & Retail$24m6.1x0.1x
n.a.
DEFM14A
All cash
Veris Residential, Inc.
2026-02-23 · Public merger · $19.00 a share
AC Residential Acquisition LP
Strategic
Real Estate$3.1bnn.a.10.8x
27%
DEFM14A
All cash
United Homes Group, Inc.
2026-02-22 · Public merger · $1.18 a share
Stanley Martin Homes, LLC
Strategic
Other$147m61.3x0.4x
n.a.
DEFM14C
All cash
Masimo Corp
2026-02-16 · Public merger · $180.00 a share
Danaher Corporation
Strategic
Healthcare$9.8bn28.0x6.4x
38%
DEFM14A
All cash
Tri Pointe Homes, Inc.
2026-02-13 · Public merger · $47.00 a share
Sumitomo Forestry Co., Ltd.
Strategic
Other$3.1bn9.3x0.9x
32%
DEFM14A
All cash
Silicon Laboratories Inc.
2026-02-04 · Public merger · $231.00 a share
Texas Instruments Incorporated
Strategic
Technology$7.2bnn.a.9.1x
n.a.
61% to VWAP
DEFM14A
All cash
Peakstone Realty Trust
2026-02-02 · Public merger · $21.00 a share
PKST Op, L.P.
Strategic
Real Estate$1.1bn29.2x10.4x
34%
4% to VWAP
DEFM14A
All cash
Ventyx Biosciences, Inc.
2026-01-07 · Public merger · $14.00 a share
Eli Lilly
Strategic
Healthcare$806mn.a.n.a.
n.a.
62% to VWAP
DEFM14A
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More